Analyst Ratings For Aptevo Therapeutics Inc (NASDAQ:APVO)
Today, Piper Jaffray Companies reiterated its Overweight rating on Aptevo Therapeutics Inc (NASDAQ:APVO) with a price target of $11.00.
There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.
The current consensus rating on Aptevo Therapeutics Inc (NASDAQ:APVO) is Buy with a consensus target price of $11.50 per share, a potential 155.56% upside.
Some recent analyst ratings include
- 8/10/2018-Aptevo Therapeutics Inc (NASDAQ:APVO) had its Overweight rating reiterated by Piper Jaffray Companies with a $11.00 price target
- 4/11/2018-Aptevo Therapeutics Inc (NASDAQ:APVO) has coverage initiated with a Buy rating and $12.00 price target
Recent Insider Trading Activity For Aptevo Therapeutics Inc (NASDAQ:APVO)
Aptevo Therapeutics Inc (NASDAQ:APVO) has insider ownership of 18.00% and institutional ownership of 34.83%.
- On 3/19/2018 Marvin L White, Insider, sold 100,000 with an average share price of $2.93 per share and the total transaction amounting to $293,000.00.
- On 11/15/2017 Randy Joe Maddux, VP, bought 25,000 with an average share price of $2.76 per share and the total transaction amounting to $69,000.00.
About Aptevo Therapeutics Inc (NASDAQ:APVO)
Aptevo Therapeutics Inc., a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn. The company's marketed products also comprise HepaGam B used for the prevention of hepatitis-B recurrence following liver transplantation in HBsAg-positive liver transplant patients, and for the treatment following exposure to hepatitis-B; and VARIZIG for use in treating following exposure to varicella zoster virus, which causes chickenpox in high-risk individuals. Its investigational stage product candidates include MOR209/ES414, a bispecific immunotherapeutic protein that is in Phase I clinical trial for metastatic castration-resistant prostate cancer; ES210, a bispecific protein therapeutic that is in pre-clinical development stage for inflammatory bowel diseases; otlertuzumab, a monospecific protein therapeutic that is in Phase II clinical trial for chronic lymphocytic leukemia; ROR1, a bispecific immunotherapeutic protein that is in preclinical development; APVO436, a bispecific protein therapeutic, which is in pre-clinical development; and other therapeutic protein product candidates for cancer. The company was incorporated in 2016 and is based in Seattle, Washington.
Recent Trading Activity for Aptevo Therapeutics Inc (NASDAQ:APVO)
Shares of Aptevo Therapeutics Inc closed the previous trading session at 4,50 0,00 0,00 % with shares trading hands.
